Advanced nanostructured medical device combining mesenchymal cells and VEGF nanoparticles for enhanced engineered tissue vascularization. by Wagner, Q et al.
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 ABSTRACT  
Aims: Success of functional vascularized tissues repair depends on vascular support system 
supply and still remains challenging. Our objective was to develop a nanoactive implant 
enhancing endothelial cell activity, particularly for bone tissue engineering in regenerative 
medicine field. Materials & methods: We developed a new strategy of tridimensional implant 
based on cell dependent sustained release of vascular endothelial growth factor (VEGF) 
nanoparticles. These nanoparticles were homogeneously distributed within nanoreservoirs onto 
the porous scaffold, with quicker reorganization of endothelial cells. Moreover, the activity of 
this active smart implant on cells was also modulated by addition of osteoblastic cells. Results 
& conclusion: This sophisticated active strategy should potentiate efficiency of current 
therapeutic implants for bone repair avoiding the need of bone substitutes.  
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INTRODUCTION 
Surgical reconstructive procedures frequently require the use of additional tissues (autograft, 
xenograft, allograft) to restore the physiological functionality of damaged tissues. To overcome 
the complications associated with these methodologies (site morbidity, limited availability and 
host tissue reactivity), cell-based tissue engineering strategies using sophisticated biomaterials 
have been developed and represent a promising part of the regenerative medicine field. In the 
recent years, a plethora of advanced biomaterials mimicking extracellular matrix were designed 
based on the micro- and nano-scale environment of tissues, using nanotechnologies as 
graphene, nanogrooves and carbon nanotubes [1-8]. More recently, and with the development 
of the third generation materials, there has been increasing interest in developing nanoparticles 
and nanoreservoirs containing active molecules able to bio-activate scaffolds [9-14].  
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Bone regeneration is a complex, well-orchestrated physiological process, which occurs during 
normal healing of fractures, and is involved in continuous remodeling throughout adult life. In 
the past, a lot of active materials have been developed to improve bone tissue repair in vivo [15-
18]. The first generation of biomaterials developed involved inert materials without any 
interaction with another component (prostheses…). Second generation biomaterials (bioactive 
coating, bio-mimicking materials) were developed to promote biological activity while 
supporting implant functions, and were either resorbable or bioactive. The third generation 
biomaterials are a combination between medical device and biological components (bioactive 
protein coating, endothelialization) and possess both bioresorbable and bioactive properties 
[19,20].  
Applications for bone tissue engineering are various and depend on the severity of injuries to 
repair. The prosthesis domain aims for replacement after ablation due to severe injuries, the 
bone substitute domain, targets the substitution of important lesions (until 60 cm3) to prevent 
ablation. This domain needs to use materials that mimicking the mechanical properties of the 
healthy bone. More recently, the domain of regenerative medicine was developed to avoid 
filling by substitute, and promote the tissue regeneration by materials totally replaced by a 
functional and biological tissue without clear high mechanical properties. During the last few 
years, sophisticated biomaterials for bone regenerative medicine were developed in clinic, for 
example in treatment of non-union fractures or with guided tissue regeneration in the 
periodontal disease treatment. Those materials can be obtained made bioactive by adding living 
cells or active growth factors. Among these strategies for bone tissue regeneration, two kinds 
of active materials can be considered: (i) materials combined with active molecules targeting 
bone tissue regeneration (BMP-2, BMP-7) [15-18, 21-26] or (ii) active materials indirectly 
acting on bone repair through combination with angiogenic factors (VEGF, Ang1) [27-32], 
which have gained increased attention recently.  
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Indeed, vascularization of biomaterials prior to their implantation is a key feature for tissue 
repair as establishment of a vascular network provides nutrients, soluble factors, phosphate and 
calcium necessary for the bone healing process. For healthy tissue repair, the formation of blood 
vessels in 3D engineered biomaterials still remains challenging today [27-29, 33]. In order to 
increase vascularization within the implanted site, several active angiogenic materials were 
developed with majority based on cell activities [34-36] or added factors activity [30-32]. One 
of the main growth factor involved in angiogenesis is VEGF165 (Vascular Endothelial Growth 
Factor) which acts as an initiator and a modulator of the signaling cascade resulting in 
proliferation and migration of endothelial cells toward formation of new blood vessels [37, 38]. 
Moreover, VEGF possesses a pivotal role during bone healing [38], and the sustained release 
of this growth factor was shown to promote the efficacy of bone regeneration [30]. Not only 
does VEGF activate proliferation and migration of endothelial cells, but it also recruits 
mononuclear and macrophage cells, which produce additional angiogenic factors [39]. 
Consequently, during the last few years, tridimensional scaffolds associated with endothelial 
cells were developed for the cell-based strategy with the goal to promote biomaterials 
vascularization [33-36]. Various studies have reported the development of VEGF loaded 
nanoparticles for bone regeneration, wound healing angiogenesis, or inhibition of the graft 
shrinkage [40-43]. Most of these models can offer a controlled release of VEGF, depending on 
various parameters (temperature, pH, …). Herein, via entrapping VEGF-NPs in active 
nanoreservoirs, we can obtain cell-contact dependent access of NPs, depending solely of cells 
biological needs, avoiding short lived-effect and instability [44]. Moreover, this strategy of 
nanoreservoirs with chitosan allows keeping NPs with the biomaterials into the site of damage, 
and protected them from degradation activity due to their short life span, contrary to a passive 
release and diffusion in situ. Human umbilical vein endothelial cells (HUVECs) are easily 
extractable and expanded to large numbers. These cells are frequently used for in vitro studies 
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of angiogenesis since they are able to spontaneously organize into capillary-like structures 
without the help of additional angiogenic growth factors, and can spontaneously anastomose 
with the host vasculature [29, 45, 46].  
Recently, we developed via electrospinning method a thick porous 3D nanofibrous poly(ε-
caprolatcone) (PCL) scaffold able to accelerate the regeneration of a robust mineralized bone 
[22, 23, 47]. Herein, we have developed a double strategy combining both (i) HUVECs, and 
(ii) VEGF-nanoparticles (VEGF-NPs) active 3D nanofibrous scaffold to improve 
vascularization in tissue engineering for regenerative medicine applications focusing on bone 
regeneration. VEGF nanoparticles were used and integrated to the scaffold employing the layer-
by-layer technology, enabling an active cell-dependent release of the active molecule [14, 48]. 
Moreover, mesenchymal cells (human primary osteoblasts) were used to increase the efficiency 
of the designed nanoactive 3D scaffold, firstly by adhesion of endothelial cells (HUVECs), and 
then by improving endothelial cells activity.  
MATERIALS & METHODS 
3D nanofibrous PCL scaffold preparation  
PCL 80 kDa, analytical grade, was obtained from Perstorp (Malmö, Sweden). The PCL solution 
was prepared as previously described [22, 23, 47]: a solution of PCL (23% w/v in 
dimethylformamide: methylene chloride 1:1 v/v) was electrospun at high voltage (20 kV at the 
beginning), which was increased during the process (ending at 26 kV). The electrospinning 
device (EC-DIG electrospinning apparatus; IME Technologies, Eindhoven, Netherlands) 
delivered the solution at a constant rate of 1.2 mL/h in a 35% humidity and 30 °C atmosphere. 
The distance between the needle and the collector was set at 16 cm. The electrospun jet was 
focused in a 25 mm hole within a 2.5 mm-thick poly-(methyl methacrylate) mask plate placed 
over the conductor. The electrospining process was stopped when the designed material reached 
a thickness around 10 mm. Pieces of 3mm diameter and 700 um of thickness were then cut for 
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the experiments. The 3D electrospun nanofibrous membranes were kept in a desiccator at 45°C 
to remove residual solvents.  
Preparation of VEGF-NPs and VEGF-NPs (HA)  
Chitosan hydrochloride (CS) (30-400 kDa, HEPPE medical chitosan GmbH (HMC+), 
Germany) nanoparticles (NPs) were produced using an ionotropic gelling method. Sodium 
tripolyphosphate (TPP) (85%, Sigma-Aldrich Co., St Louis, MO, USA) solution (1 mg/mL) 
was added drop-wise to chitosan hydrochloride solution (1 mg/mL) at a ratio of 1:5 w/w under 
constant stirring at room temperature. The resultant NPs suspension was left under stirring for 
20 minutes to ensure complete particle formation. hVEGF165 loaded NPs were obtained using 
the same method incorporating VEGF (VEGF-NPs) 200 µl (0.05 % w/v) with TPP solution. 
Chitosan/hyaluronic acid NPs were prepared by the same ionotropic gelling method, with 
modifications. Hyaluronic acid (HA) (10-20 kDa, Lifecore Biomedical, USA) (0.625 mg/mL) 
was dissolved in ultrapure water and mixed with TPP solution (1 mg/mL) at a ratio 3.75:1 w/w 
under constant stirring at room temperature. This poly-anionic phase was then added drop-wise 
to CS (1 mg/mL) at a ratio of 1:1.80 w/w (HA/TPP: CS) under constant stirring at room 
temperature. VEGF-NPs (HA) were obtained using the same method incorporating VEGF 
(VEGF-NPs (HA)) 200 µl (0.05 % w/v) with TPP/HA solution. To obtain dry powders, all were 
freeze-dried. Samples were frozen at -80 °C, 24h with trehalose at ratio 1:8 (Trehalose: CS) and 
then freeze-dried for 28 hours (Virtis Advantage, SP Scientific, USA). 
Nanoparticles’ size characterisation 
Particle size analyses of freeze-dried samples were performed using dynamic light scattering 
(DLS) (Zetasizer Nano series DTS 1060, Malvern Instruments Ltd, UK). 2mg of VEGF-NPs 
and VEGF-NPs (HA) were dispersed in 2 mL of MES buffer (2-N-morpholino ethane sulfonic 
acid MES; Sigma-Aldrich Co., 0.04M MES, 0,15M NaCl, pH 5.5), loaded into a cuvette and 
data recorded at 25 °C (n = 3 suspensions). 
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PLL-FITC staining of VEGF-NPs 
Glass slides were treated with Poly-glutamic acid (Sigma-Aldrich) (500 µm/mL) for 15 
minutes, rinsed with PBS for 15 minutes followed by addition with VEGF-NPs (3 mg/mL) for 
15 minutes at room temperature. Finally, samples were rinsed in PBS for 15 minutes and then 
with poly-lysine fluorescein-isothiocyanate (PLL-FITC) for 15 minutes. Glass slides were then 
observed under an epifluorescent microscope (LEICA DM 4000 B). 
Transmission electron microscopy observation For visualisation of VEGF-NPs and VEGF-
NPs (HA), freeze-dried sample was dispersed in water and applied to an electronic microscopy 
copper grid and stained with 2% phosphotungstic acid solution. The NPs were imaged by 
transmission electron microscopy (TEM) using an FEI CM 120 BioTwin transmission electron 
microscope (Philips Electron Optics BV, Netherlands) using acceleration voltage 120.0 kV 
(CM120, Philips Co, The Netherlands). 
VEGF-NPs nanoreservoirs formation on 3D PCL scaffold  
VEGF-NPs were dissolved at 2 mg/mL in MES buffer (pH 5.5) and chitosan was added at a 
concentration of 0.5 mg/mL (Protasan UP CL 113, Novamatrix, Sandvika, Norway). The 
creation of nanoreservoirs containing VEGF-NPs on the nanofibers was carried out using the 
layer-by-layer technology: briefly the 3D electrospun scaffold was dipped 6 times during 15 
minutes alternately in solutions of nanoparticles and BSA gold (Aurion, Binnenhaven, 
Wageningen, The Netherlands) or BSA (200 ng/mL) (Bovine Serum Albumin, Euromedex, 
Souffelweyersheim, France). Each bath was followed by a rinsing step with MES buffer. 
Scanning electron microscopy observation 
To analyse the morphology of the functionalized 3D PCL scaffolds, samples were fixed in 
paraformaldehyde 4% for 10 minutes at 4 °C, then dehydrated and observed with a scanning 
electron microscope (SEM Hitachi TM 1000 or FEG Sirion XL; FEI) in conventional mode 
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(high vacuum) by collecting either secondary electrons or a combination of secondary and retro-
diffused electrons.  
Cell culture 
Human umbilical vein endothelial cells (HUVECs) and human primary osteoblasts (HOBs) 
were obtained from PromoCell (Heidelberg, Germany). The cells were cultured in specific 
growth medium (endothelial cell growth medium, osteoblast growth medium, respectively, 
PromoCell). The cells were incubated at 37 °C in a humidified atmosphere of 5% CO2. When 
cells reached confluence, they were harvested with trypsin (Ozyme) and sub-cultured.  
HUVECs culture in collagen gel 
HUVECs culture medium was mixed with collagen I (2 mg/mL) (Institut de biotechnologie 
Jacques Boy, Reims, France) and NaOH (0.1M) was added to adjust the pH of the preparation. 
The cellular suspension of HUVECs, containing or not VEGF-NPs (2 mg/mL), was added and 
the final solution was seeded on 3D PCL scaffolds or in small Petri dishes, in a humidified 
atmosphere at 37 °C and 5% CO2 to polymerise the collagen gel. Cells in collagen gel on 
scaffolds were then cultured in their corresponding growth medium in a humidified atmosphere 
at 37 °C and 5% CO2. 
Cell viability  
Alamar Blue® (Thermo Fisher Scientific, Waltham, MA, USA) was used to assess cell 
metabolic activity over time. In this study, 4 x 104 human osteoblasts were first seeded on 3D 
PCL scaffolds containing or not nanoreservoirs of VEGF-NPs. After 7 days, 4 x 104 HUVECs 
were seeded on this pre-coated scaffold, and samples were cultured during a total of 28 days in 
a proliferative medium consisting of 50% HOB medium/50% HUVEC medium. Analyses were 
performed at D7, 9, 14, 21, and 28 days by culturing cells with a solution of 10% Alamar Blue®/ 
Dulbecco’s Modified Eagle’s Medium without phenol red (Lonza, Levallois-Perret, France) 
during 4 hours in a humidified atmosphere at 37 °C and 5% CO2. The same experiments were 
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performed with HUVECs cells in collagen gel seeded on 3D PCL equipped or not with VEGF-
NPs (D3, D7, D14, D21, and D28). Optical density of supernatants was measured at 575 and 
590 nm in order to determine the percentage of Alamar Blue® reduction. Statistical analyses 
were obtained by t-paired student test. 
Subcutaneous in vivo implantation in nude mice 
All procedures regarding animals and tissues were designed in agreement with the 
recommendations of the European Union (2010/63/EU), and were performed according to 
authorized investigator Dr N. Jessel (Director of the Osteoarticular and Dental Regenerative 
Nanomedicine team), holder of a personal license from Prefecture du Bas-Rhin (number 67-
315), who oversaw experiments done on mice. All experiments were performed in the 
Animalerie Centrale de la Faculté de Médecine de Strasbourg with the approval number A 67-
482-35 from the Veterinary Public Health Service of the Préfecture du Bas-Rhin, representing 
the French Ministry of Agriculture, Department of Veterinary Science.  
The study involved nude male mice (Crl: NIH-Foxn1nu ; Charles River, L’arbresle, France) 6 
weeks of age. The mice were anesthetized with an intra-peritoneal injection of 100 mg/kg of 
ketamine (VIRBAC Santé Animale; Centravet, Nancy, France) and injection of 10 mg/kg of 
Xylazine (Rompun® 2%) and animals were placed in a ventral decubitus position on a heating 
plate, under strict aseptic conditions. After skin incision, 3 mm-long 3D PCL scaffolds, with 
and without VEGF-NPs nanoreservoirs, which had been seeded with HOBs and HUVECs for 
2 weeks (D14), were subcutaneously implanted in the mice. The skin was then sealed with 
sutures and the mice’ behaviour was observed after waking up and during the incubation time. 
The mice were sacrificed with an intra-peritoneal injection of a lethal dose of ketamine and the 
samples were extracted after 4 and 8 days of implantation.  
Immunofluorescence staining 
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Samples were fixed with 4% paraformaldehyde solution for 10 minutes at 4 °C and 
permeabilised with a 0.1% Triton X-100 solution for an hour at room temperature. To 
specifically label the surface of endothelial cells, samples were incubated overnight at 4 °C with 
mouse monoclonal anti-CD31 (1/400, Santa Cruz Biotechnology Inc., Dallas, TX, USA), 
followed by 1 hour incubation at room temperature with the secondary anti-IgG of mouse 
coupled to Alexa Fluor 488 (Life Technologies). Samples were then incubated for 20 minutes 
in a solution of Alexa fluor 546-conjugated phalloïdin (1/200, Molecular Probes; Life 
Technologies, Fisher Scientific, Illkirch, France). After this step, a solution of 200 nM DAPI 
(Sigma-Aldrich) was added to mark the nuclei of exposed cells. Observation of the samples 
was carried out using an epifluorescence microscope (Leica DM 4000 B). 
RESULTS 
VEGF-NPs to design a nanoactive 3D biomaterial 
To increase the efficiency of tissue repairing in vivo, we developed an active tridimensional 
biomaterial equipped with VEGF-NPs. Our team previously developed a 3D porous PCL 
scaffold (Figure 1A) by the electrospinning method, for bone regeneration [22, 23, 47]. As 
previously described, this 3D-PCL implant (Figure 1B) present a superposition of spaced 
stratified layers of PCL nanofibers, facilitating macropores formation. This is an interconnected 
microporous/ macroporous scaffold, constituted of nanofiber
689±45 nm in diameter) able to mimic the collagen present in the extracellular matrix of healthy 
bone tissue, in favor of blood vessel colonization [22, 23, 47]. In this study, to make this 3D 
nanofibrous scaffold active, we first manufactured VEGF-NPs, and then added these to our 3D 
biomaterial. The VEGF-NPs are composed of chitosan forming the shell of the nanoparticles, 
and VEGF encapsulated within the nanoparticles. These VEGF-NPs were obtained by inotropic 
gelling and freeze-drying method (Figure 1C). These nanoparticles have a mean size of 175.4 
± 4.1 nm for VEGF-NPs and 167.5 ± 10.6 nm for VEGF-NPs containing hyaluronic acid 
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(VEGF-NPs (HA)) (Figure 1D). These observations, together with TEM observations (Figure 
1E and 1F), didn’t show significant differences in size between the two types of VEGF-NPs. 
Then, we functionalized the 3D Scaffold (Figure 2) by depositing VEGF-NPs. To this end, we 
employed our nanoreservoirs technology using the LbL technique [14]. After having tested 
different concentrations of VEGF-NPs to form the nanoreservoirs with chitosan solutions, we 
have found that the greatest condition to obtain a homogeneous deposition of NPs all along 
nanofibers of the scaffold, and in all the thickness of our 3D nanofibrous PCL was obtained 
with a concentration of VEGF-NPs of 2mg/mL (data not shown). The LbL (BSA/VEGF-NPs)6-
treated nanofibers (Figure 2B) showed a more homogeneous deposition of VEGF-NPs 
encapsulated within nanoreservoirs all along the fibers (Figure 2B), confirmed by co-
localization with Gold-labeled BSA LbL (Figure 2C), compared to a single adsorption of 
VEGF-NPs (Figure 2A). Hence, we were able to design a porous tridimensional scaffold 
mimicking ECM and homogeneously equipped with VEGF-NPs, ready to receive endothelial 
cells.  
VEGF-NPs active 3D Scaffold effect on endothelial cells (GEL) 
As endothelial cells require collagen motifs to adhere to a biomaterial, we used collagen gel to 
increase endothelial cells adhesion to the 3D PCL scaffold. Behavior of endothelial cells in the 
presence of VEGF-NPs was first analyzed and results were observed by fluorescence staining. 
In the presence of VEGF-NPs, endothelial cells showed regular linear, tubule-like, cell 
organization, (Figure 3C), compared to HUVECs cultured without additional VEGF-NPs 
(Figure 3B). As the endothelial cells organization in the presence of VEGF-NPs was confirmed 
in the collagen gel, we next analyzed the behavior of endothelial cells on the VEGF-NPs active 
3D-PCL scaffold. In this condition, Alamar Blue® test showed no significant difference 
between cells cultured on VEGF-NPs scaffold and non-functionalized scaffold at each time 
point (Figure 3A), showing biocompatibility of VEGF-NPs nanofibrous scaffold with 
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endothelial cells. However, significant difference was found for the non-functionalized scaffold 
between D3 and D28. This result could be explained by a loss of collagen gel containing 
endothelial cells, during the incubation time. Endothelial cells reorganization was also observed 
in this active tridimensional material (Figure 3E). Hence, we showed that our 3D PCL scaffold 
equipped with VEGF-NPs was active, and biocompatible for rapid endothelial cells activity and 
reorganization.  
Double effect of VEGF-NPs active 3D PCL and HOB on Endothelial cells (HOB) 
 We sequentially used mesenchymal cells (HOBs) as a coating of VEGF-NPs active 3D PCL, 
for the adhesion of endothelial cells.  
We first investigated the biocompatibility of our 3D VEGF-NPs active nanofibrous material 
pre-seeded with HOBs during 7 days, and then covered by endothelial cells. Analysis showed 
an increase in the metabolic activity all along the culture and after seeding of endothelial cells 
on HOBs (Figure 4A). Interestingly, the metabolic activity was more important when 
endothelial cells were seeded on a HOB pre-coated VEGF-NPs active scaffold (Figure 4A) 
compared to cells seeded in collagen gel (Figure 3). At D14, a significant difference occurred 
with cells cultured on VEGF-NPs biomaterials, showing more significant metabolic activity 
than cells without VEGF-NPs (p = 0.018) (Figure 4A). Moreover, at D28, more tubule-like 
endothelial structures were observed on the VEGF-NPs 3D PCL scaffold (Figure 4C). These 
results were observed by indirect immunofluorescence against endothelial specific marker 
CD31 (Figure 4B, C). Endothelial cells (visible in green) were first able to adhere to the scaffold 
without any collagen gel (Figure 4B) and second, they were able to form tubule-like and linear 
structures on this double active implant (Figure 4C). We then subcutaneously implanted our 
double active scaffold in nude mice to observe its influence on host endothelial cells (Figure SI 
1). After 4 days and 8 days in vivo, the macroscopic view of the implant revealed that when 
equipped with VEGF-NPs NRs, it was able to increase the host vasculature recruitment (host 
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endothelial cells) towards implant by 20% compared to non-fonctionnalized one (Figure SI 1). 
These results show the potential double activity of our scaffold with regard to endothelial cells. 
The effect of our implant on tubule-like structures formation was obtained by the addition of 
VEGF-NPs and improved by the pre-coating with human osteoblast cells HOBs.  
DISCUSSION 
VEGF-NPs encapsulated in nanoreservoirs on a 3D scaffold to accelerate implant 
vascularization. 
In the last decade, a large variety of active biomaterials have been developed for tissue 
engineering [1,12-14, 21-26, 49-60]. Focusing on either cartilage or bone tissue regeneration 
and controlled and active release of growth factor, our team has developed several active 
nanofibrous materials equipped with active nanoreservoirs of BMP-2 and BMP-7 [14, 21-26]. 
These natural collagen (Bio-Gide®) or polymeric (PCL) implants showed great potential in 
regenerative nanomedicine for bone regeneration with primary autologous cells (human 
mesenchymal stem cells, human primary osteoblasts) [14, 21-26]. The tridimensional 
electrospun PCL nanofibrous scaffold appeared to be promising due to its biomimicking 
architecture, with high porosity and enhanced pore interconnectivity, improving cell 
colonization and infiltration [22, 23]. Particularly for bone tissue engineering and blood supply 
during the early stages of post-implantation, it is necessary to provide a fast and sufficient blood 
perfusion within implants for calcium and phosphorus distribution, nutrients and oxygen 
diffusion, and elimination of wastes. Bone healing can be improved by adjusting the speed of 
vascularization and during the last 5 years, attempts have been made to increase vascularization 
in the tissue-engineering field [27-29, 33, 38-39]. Hence, basic strategies using scaffolds 
focused firstly on the use of cells (HUVEC, EPC) [30-32], and secondly on the use of active 
molecules (VEGF, Ang1, ...) operating on endothelial cells [34-36] to promote proliferation, 
migration, sprouting and establishment of functional blood vessel. In our strategy, we chose to 
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use not only VEGF active molecules (VEGF-NPs), but also endothelial and mesenchymal cells. 
VEGF plays a pivotal role in bone healing and remodeling. Moreover, if a local excessive dose 
of VEGF is released over a short time period, this leads to generation of non-functional and 
leaky blood vessels. To this end, a more sustained release over time is required to promote 
angiogenesis [30], which is the case in our strategy of nanoreservoirs. Hence, the effects of 
VEGF on biological processes are dose dependent. Our technology of nanoreservoirs created 
by LbL allowed a homogeneous distribution of VEGF-NPs all over the scaffold and enabled an 
active and controlled released of VEGF-NPs, dependent on the cells contact to the 
nanoreservoirs [14, 48]. In our strategy, HUVECs cells will recognize and adhere to chitosan, 
whether it is present on NPs or in our nanoreservoirs functionalization. In the case of active 
nanoreservoirs, cells will degrade by enzymatical reaction nanoreservoirs and will have an 
access to the NPs containing VEGF. Moreover, encapsulated active molecules represent a 
major advantage considering the short half-life of the VEGF growth factor (50 min). Our 
nanoreservoir technology overcomes potential damages that can occur to VEGF by protecting 
it within nanoreservoirs. 
Double effect of VEGF-NPs and mesenchymal cells (HOBs) on endothelial cells 
organization.  
Our nanofibrous scaffold was obtained from polycaprolactone by electrospining. This 
nanostructured material has already shown its efficacy in terms of bone regeneration with 
mesenchymal stem cells and primary human osteoblastic cells [14, 21-23]. Moreover, this 3D 
material, leads to an homogeneous attachment of osteoblastic cells [14, 21-23]. When dotted 
with chitosan-growth factor nanoreservoirs, 3D PCL present an adhesion of cells specifically 
in clusters onto the nanoreservoirs, contrary to non-functionalized PCL. The adherence of 
osteoblastic cells in cluster will also create a cluster of endothelial cells adhesion where they 
will reorganise, thanks to the angiogenic environment that could be provided by osteoblastic 
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cells. However, adhesion of endothelial cells requires collagen moieties [61, 62]. Hence, in this 
study we used a collagen gel to improve endothelial cells adhesion. In these conditions, 
HUVECs were able to re-organize linearly, in the presence of VEGF-NPs directly in collagen 
gel or onto the 3D PCL scaffold. However, the use of collagen with 3D PCL scaffold presents 
technical limitations. Hence, in this study we adapted another alternative to improve endothelial 
cells adhesion to PCL, with the use of functionalized PCL scaffolds pre-coated with 
mesenchymal cells. The sequential seeding in our study, with mesenchymal osteoblastic cells 
prior to endothelial cells lead to a primo-access to the VEGF for mesenchymal cells. These cells 
will serve as i) anchor to endothelial cells attachment to the biomaterial and ii) secretor of 
growth factor activation reorganisation of endothelial cells. 
In this study we developed an active scaffold able to improve and accelerate endothelial cells 
organization in tubule-like structures and host vasculature recruitment in the implant after 
implantation to ameliorate tissue-engineering efficacy. After showing the efficiency of VEGF-
NPs on HUVECs behavior, we used HOBs to improve their adhesion on PCL scaffold. 
Actually, cells of mesenchymal origin, either by their capacity to secrete extracellular matrix 
(decellularized matrix) or by their own particular nature, were exploited to improve cell 
attachment on non-collagen materials [48, 63, 64]. Process of angiogenesis and bone formation 
are thought to be in close interaction in bone healing. Moreover HOBs and mesenchymal stem 
cells are known to increase the stability of in vitro and in vivo tubule-like structure formation 
by endothelial cells [29, 65]. Recently, much attention has been implemented in endothelial 
cells as mediators of osteogenic differentiation, since the combined use of mesenchymal cells 
(HOBs, MSCs) significantly enhanced the ability of osteogenic differentiation tissue in vitro 
[22, 23, 66-68]. With the combination of the two strategies in one material (VEGF-NPs and the 
use of HOBs), we were able to accelerate host vascularization of the implant in vivo. These 
results could be explained by the fact that VEGF was not only available via our NPs for 
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exogenic endothelial cells added to the scaffold, but also that HOBs and HUVECs used 
synergistically secrete more angiogenic factors compared to HUVECs alone [69]. Moreover, 
the access of HOBs to the VEGF-NPs can increase the secretion of angiogenic factors in the 
implant, resulting in the VEGF molecules acting directly on osteoblasts proliferation and 
migration [70]. Thus, in our double strategy, Endothelial cells will adhere to the VEGF-NPs 
material via the previous matrix secretion of HOBs. HOBs, degrading nanoreservoirs by 
enzymatic reaction, will have an access to the VEGF-NPs, and will secrete angiogenic factor 
used by HUVECs. Based on the capacity of exogenous endothelial cells to anastomose with 
host vasculature [29], we subcutaneously implanted our double active implant and observed an 
enhanced initiation of host vasculature in the implant containing VEGF-NPs compared to the 
non-functionalized scaffold. Controlled drugs release is an important field for human health. In 
most cases, the developed materials for regenerative medicine, using VEGF [40-43] lead to a 
high-dose passive release with overdoses, side effect, and the progression of tumors [71], 
particularly for regeneration of tissues compromised after irradiation. With our double strategy, 
VEGF release is sustained and dependent of cells adhesion and reliant on their own needs. 
Moreover, the growth factor release is localized at the desired site, avoiding thus side effects. 
CONCLUSION 
In the last few years, new tissue-engineering strategies for bone repair have focused on 
vascularization to improve the quality of repaired tissues. In this work, our aim was to develop 
a new strategy of active implant leading to improve endothelial cells organization. This strategy 
can improve vascularization in situ and can enhance the repair potential of tissues in vivo. In 
this study, we developed a 3D biodegradable and polymeric scaffold, highly porous, active for 
endothelial cells organization and improving the speed of cell reorganization by incorporating 
VEGF-NPs. This scaffold was active towards endothelial cells not only via the incorporation 
of VEGF-NPs, but also via incorporation of osteoblast cells as pre-coating on our 3D PCL 
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nanofibrous scaffold. This work highlights the nanofibrous implant potential, offering an active 
and sustained release of angiogenic growth factor for regenerative medicine application. The 
double effect obtained in vivo with this living implant could be transfered to the clinic, taking 
advantage of the therapeutic potential of mesenchymal stem cells. We also think that this new 
generation of sophisticated implant is adaptable for engineering of other tissues, since it can be 
equipped with other kinds of cells or active molecules.  
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Summary points 
- Design of a tridimensional active material for regenerative medicine 
- We have developed here a VEGF active tridimensional polymeric material containing a 
homogeneous repartition of nanoparticles with a cell-contact dependant active release. 
- The entrapment of VEGF nanoparticles in nanoreservoirs is able to have an effect on 
endothelial cells behaviour. 
-This material offers an active and sustained release of angiogenic growth factor for 
regenerative medicine application. 
- Double strategy to promote endothelial cell reorganization for regenerative medicine 
-The adhesion of mesenchymal cells onto the VEGF nanoreservoirs material enables to 
potentiate its own capacity to act on endothelial cells behaviour.  
-The use of mesenchymal cells and VEGF nanoparticles can increase the endothelial cells 
reorganisation 
- This double strategy can promote angiogenesis after implantation and can potentiate the 
current implants used in regenerative medicine. 
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